Navigation Links
Eidogen-Sertanty Licenses TIP to the FDA
Date:12/8/2009

SAN DIEGO, Dec. 8 /PRNewswire/ -- Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today they have licensed their Target Informatics Platform (TIP) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).

Under the terms of the license, scientists within NCTR will have access to the complete TIP structural knowledgebase via onlineTIP as well as access to the TIP/Workgroup technology for internal research. Eidogen-Sertanty will also participate in several NCTR-led projects including the multi-year PADRE project (MAQC-IV), which is focusing on the modeling of drug-protein interactions to identify new genetic variations that may lead to serious adverse drug reactions.

"We're extremely pleased to have licensed the TIP technology to the FDA/NCTR," said Dr. Steven Muskal, Eidogen-Sertanty's Chief Executive Officer. "We very much look forward to having a positive impact in the FDA's effort to predict serious adverse drug reactions at the individual patient level."


Eidogen-Sertanty contact:

Steve Muskal
760-651-2885
pr@eidogen-sertanty.com

About Eidogen-Sertanty

Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty's unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services, please visit www.eidogen-sertanty.com.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE Eidogen-Sertanty


'/>"/>
SOURCE Eidogen-Sertanty
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France
2. GeneGo Licenses MetaCore to Proteostasis Therapeutics
3. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
4. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
5. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
6. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
7. Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane
8. Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
9. Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
10. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
11. Implicit Licenses Clinical Stage Antibody Program From Lilly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs ... to include an array of biochemical analyses critical for Lead Discovery. The ... hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, and ...
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
(Date:2/23/2017)... ... ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC 501(c)3 non-profit, ... is to advance global health and highlight the greater good of clinical trial participation ... trial volunteer. The vision of GGI is to serve as a philanthropic connector between ...
Breaking Biology Technology:
(Date:2/6/2017)... 6, 2017 According to Acuity Market ... border authorities to continue to embrace biometric and ... 2143 Automated Border Control (ABC) eGates and 1436 ... more than 163 ports of entry across the ... achieving a combined CAGR of 37%. APC Kiosks ...
(Date:2/2/2017)... Fla. , Feb. 2, 2017   ... a clinical-stage immuno-oncology company specializing in the development ... for the treatment of cancer and metastatic disease, ... scale-up and GMP manufacturing of a second clinical ... vaccine targeting folate receptor alpha. The manufactured vaccine ...
(Date:2/1/2017)... -- IDTechEx Research, a leading provider of independent market ... of a new report, Sensors for Robotics: Technologies, Markets and ... ... ... Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, ...
Breaking Biology News(10 mins):